The Eµ-TCL-1 mouse model of chronic lymphocytic leukemia

Background: Chronic lymphocytic leukemia (CLL) is a heterogenous disease characterized by the accumulation of CD5+/CD19+ B cells in all lymphoid compartments. Apart from hematopoietic stem cell transplantation, current treatment options are not curative, and in many patients, the disease eventually...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) 2016-12, Vol.69, p.S110
Hauptverfasser: Chin, HS, Egle, A, Khaw, SL, VanDelft, MF, Huang, DC
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page S110
container_title European journal of cancer (1990)
container_volume 69
creator Chin, HS
Egle, A
Khaw, SL
VanDelft, MF
Huang, DC
description Background: Chronic lymphocytic leukemia (CLL) is a heterogenous disease characterized by the accumulation of CD5+/CD19+ B cells in all lymphoid compartments. Apart from hematopoietic stem cell transplantation, current treatment options are not curative, and in many patients, the disease eventually relapses or becomes resistant to standard therapies. Freclinical evaluation of novel therapeutic approaches for CLL has been limited by the our inability to propagate patient samples in in vitro culture for prolonged periods and the lack of representative cell lines or mouse models. Croce et al. developed and characterised the Ek-TCL-1 mouse model, where the oncogene TCL-1 is overexpressed in B cells, as a putative CLL model. The aim of our studies is to further characterise the mouse model using next-gen sequencing approaches. Materials and Methods: Next-geri sequencing was performed using RNA isolated from CD5+/CD19 cells from the spleens of transgenic mice. We compared the transcriptome profiles of murine leukemic cells with normal B cell subsets and a cohort of human CLL patients (Ferreira et al., 2014). Results: We show that the molecular signatures derived from CD517CD1 9+ leukemic cells from ER-TCL-1 mice are distinct from other normal B cell subsets. Strikingly, molecular signatures of these leukemias demonstrate minimal overlap with those of the those of most human population (Ferreira et al., 2014). Nonetheless, more stringent analysis revealed that the mouse model does bear a close resemblance to a subgroup of human CLL characterized by high TCLI expression. TCL1 overexpression has been associated with adverse outcome in CLL patients. Interestingly, unlike prototypical CLL disease, dysregulation of BCL-2 family protein expression was not detected in leukemic cells from Et-TCL-1 transgenic mice, which appear refractory to the inhibition of BCL2, at least in vitro. Moreover, the leukemias isolated from sick mice showed a surprisingly wide range of sensitivity to standard-of-care agents such as fludarabine. Conclusions: Taken together, our studies suggest that the leukemias which develop in ER-TCL-1 transgenic mice represent a highly aggressive, chemorefractory subtype of CLL. The goals of our ongoing studies are to further characterize this model of CLL and utilize it to test novel therapeutic approaches for treating CLL, particularly chemorefractory disease.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2037440181</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2037440181</sourcerecordid><originalsourceid>FETCH-proquest_journals_20374401813</originalsourceid><addsrcrecordid>eNpjYuA0tDC31DWwMDViYeA0sDS11LUwMLHkYOAqLs4yMDAwtzAx4GSwDMlIVXA9tFU3xNlH11AhN7-0OBVIpqTmKOSnKSRnFOXnZSYr5FTmFmTkJ1eWgNippdmpuZmJPAysaYk5xam8UJqbQdnNNcTZQ7egKL-wNLW4JD4rv7QoDygVb2RgbG5iYmBoYWhMnCoASAg3cw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2037440181</pqid></control><display><type>article</type><title>The Eµ-TCL-1 mouse model of chronic lymphocytic leukemia</title><source>Access via ScienceDirect (Elsevier)</source><creator>Chin, HS ; Egle, A ; Khaw, SL ; VanDelft, MF ; Huang, DC</creator><creatorcontrib>Chin, HS ; Egle, A ; Khaw, SL ; VanDelft, MF ; Huang, DC</creatorcontrib><description>Background: Chronic lymphocytic leukemia (CLL) is a heterogenous disease characterized by the accumulation of CD5+/CD19+ B cells in all lymphoid compartments. Apart from hematopoietic stem cell transplantation, current treatment options are not curative, and in many patients, the disease eventually relapses or becomes resistant to standard therapies. Freclinical evaluation of novel therapeutic approaches for CLL has been limited by the our inability to propagate patient samples in in vitro culture for prolonged periods and the lack of representative cell lines or mouse models. Croce et al. developed and characterised the Ek-TCL-1 mouse model, where the oncogene TCL-1 is overexpressed in B cells, as a putative CLL model. The aim of our studies is to further characterise the mouse model using next-gen sequencing approaches. Materials and Methods: Next-geri sequencing was performed using RNA isolated from CD5+/CD19 cells from the spleens of transgenic mice. We compared the transcriptome profiles of murine leukemic cells with normal B cell subsets and a cohort of human CLL patients (Ferreira et al., 2014). Results: We show that the molecular signatures derived from CD517CD1 9+ leukemic cells from ER-TCL-1 mice are distinct from other normal B cell subsets. Strikingly, molecular signatures of these leukemias demonstrate minimal overlap with those of the those of most human population (Ferreira et al., 2014). Nonetheless, more stringent analysis revealed that the mouse model does bear a close resemblance to a subgroup of human CLL characterized by high TCLI expression. TCL1 overexpression has been associated with adverse outcome in CLL patients. Interestingly, unlike prototypical CLL disease, dysregulation of BCL-2 family protein expression was not detected in leukemic cells from Et-TCL-1 transgenic mice, which appear refractory to the inhibition of BCL2, at least in vitro. Moreover, the leukemias isolated from sick mice showed a surprisingly wide range of sensitivity to standard-of-care agents such as fludarabine. Conclusions: Taken together, our studies suggest that the leukemias which develop in ER-TCL-1 transgenic mice represent a highly aggressive, chemorefractory subtype of CLL. The goals of our ongoing studies are to further characterize this model of CLL and utilize it to test novel therapeutic approaches for treating CLL, particularly chemorefractory disease.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><language>eng</language><publisher>Oxford: Elsevier Science Ltd</publisher><subject>Animal models ; Bcl-2 protein ; CD19 antigen ; CD5 antigen ; Cell culture ; Chronic lymphocytic leukemia ; Fludarabine ; Gene expression ; Gene sequencing ; Hematopoietic stem cells ; Human populations ; Leukemia ; Lymphatic leukemia ; Lymphocytes B ; Mice ; Molecular chains ; Patients ; Protein expression ; Proteins ; Ribonucleic acid ; RNA ; Signatures ; Stem cell transplantation ; Stem cells ; Subgroups ; Transgenic mice ; Transplantation</subject><ispartof>European journal of cancer (1990), 2016-12, Vol.69, p.S110</ispartof><rights>Copyright Elsevier Science Ltd. Dec 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Chin, HS</creatorcontrib><creatorcontrib>Egle, A</creatorcontrib><creatorcontrib>Khaw, SL</creatorcontrib><creatorcontrib>VanDelft, MF</creatorcontrib><creatorcontrib>Huang, DC</creatorcontrib><title>The Eµ-TCL-1 mouse model of chronic lymphocytic leukemia</title><title>European journal of cancer (1990)</title><description>Background: Chronic lymphocytic leukemia (CLL) is a heterogenous disease characterized by the accumulation of CD5+/CD19+ B cells in all lymphoid compartments. Apart from hematopoietic stem cell transplantation, current treatment options are not curative, and in many patients, the disease eventually relapses or becomes resistant to standard therapies. Freclinical evaluation of novel therapeutic approaches for CLL has been limited by the our inability to propagate patient samples in in vitro culture for prolonged periods and the lack of representative cell lines or mouse models. Croce et al. developed and characterised the Ek-TCL-1 mouse model, where the oncogene TCL-1 is overexpressed in B cells, as a putative CLL model. The aim of our studies is to further characterise the mouse model using next-gen sequencing approaches. Materials and Methods: Next-geri sequencing was performed using RNA isolated from CD5+/CD19 cells from the spleens of transgenic mice. We compared the transcriptome profiles of murine leukemic cells with normal B cell subsets and a cohort of human CLL patients (Ferreira et al., 2014). Results: We show that the molecular signatures derived from CD517CD1 9+ leukemic cells from ER-TCL-1 mice are distinct from other normal B cell subsets. Strikingly, molecular signatures of these leukemias demonstrate minimal overlap with those of the those of most human population (Ferreira et al., 2014). Nonetheless, more stringent analysis revealed that the mouse model does bear a close resemblance to a subgroup of human CLL characterized by high TCLI expression. TCL1 overexpression has been associated with adverse outcome in CLL patients. Interestingly, unlike prototypical CLL disease, dysregulation of BCL-2 family protein expression was not detected in leukemic cells from Et-TCL-1 transgenic mice, which appear refractory to the inhibition of BCL2, at least in vitro. Moreover, the leukemias isolated from sick mice showed a surprisingly wide range of sensitivity to standard-of-care agents such as fludarabine. Conclusions: Taken together, our studies suggest that the leukemias which develop in ER-TCL-1 transgenic mice represent a highly aggressive, chemorefractory subtype of CLL. The goals of our ongoing studies are to further characterize this model of CLL and utilize it to test novel therapeutic approaches for treating CLL, particularly chemorefractory disease.</description><subject>Animal models</subject><subject>Bcl-2 protein</subject><subject>CD19 antigen</subject><subject>CD5 antigen</subject><subject>Cell culture</subject><subject>Chronic lymphocytic leukemia</subject><subject>Fludarabine</subject><subject>Gene expression</subject><subject>Gene sequencing</subject><subject>Hematopoietic stem cells</subject><subject>Human populations</subject><subject>Leukemia</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes B</subject><subject>Mice</subject><subject>Molecular chains</subject><subject>Patients</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Signatures</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Subgroups</subject><subject>Transgenic mice</subject><subject>Transplantation</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpjYuA0tDC31DWwMDViYeA0sDS11LUwMLHkYOAqLs4yMDAwtzAx4GSwDMlIVXA9tFU3xNlH11AhN7-0OBVIpqTmKOSnKSRnFOXnZSYr5FTmFmTkJ1eWgNippdmpuZmJPAysaYk5xam8UJqbQdnNNcTZQ7egKL-wNLW4JD4rv7QoDygVb2RgbG5iYmBoYWhMnCoASAg3cw</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Chin, HS</creator><creator>Egle, A</creator><creator>Khaw, SL</creator><creator>VanDelft, MF</creator><creator>Huang, DC</creator><general>Elsevier Science Ltd</general><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20161201</creationdate><title>The Eµ-TCL-1 mouse model of chronic lymphocytic leukemia</title><author>Chin, HS ; Egle, A ; Khaw, SL ; VanDelft, MF ; Huang, DC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_20374401813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animal models</topic><topic>Bcl-2 protein</topic><topic>CD19 antigen</topic><topic>CD5 antigen</topic><topic>Cell culture</topic><topic>Chronic lymphocytic leukemia</topic><topic>Fludarabine</topic><topic>Gene expression</topic><topic>Gene sequencing</topic><topic>Hematopoietic stem cells</topic><topic>Human populations</topic><topic>Leukemia</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes B</topic><topic>Mice</topic><topic>Molecular chains</topic><topic>Patients</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Signatures</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Subgroups</topic><topic>Transgenic mice</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chin, HS</creatorcontrib><creatorcontrib>Egle, A</creatorcontrib><creatorcontrib>Khaw, SL</creatorcontrib><creatorcontrib>VanDelft, MF</creatorcontrib><creatorcontrib>Huang, DC</creatorcontrib><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chin, HS</au><au>Egle, A</au><au>Khaw, SL</au><au>VanDelft, MF</au><au>Huang, DC</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Eµ-TCL-1 mouse model of chronic lymphocytic leukemia</atitle><jtitle>European journal of cancer (1990)</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>69</volume><spage>S110</spage><pages>S110-</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Background: Chronic lymphocytic leukemia (CLL) is a heterogenous disease characterized by the accumulation of CD5+/CD19+ B cells in all lymphoid compartments. Apart from hematopoietic stem cell transplantation, current treatment options are not curative, and in many patients, the disease eventually relapses or becomes resistant to standard therapies. Freclinical evaluation of novel therapeutic approaches for CLL has been limited by the our inability to propagate patient samples in in vitro culture for prolonged periods and the lack of representative cell lines or mouse models. Croce et al. developed and characterised the Ek-TCL-1 mouse model, where the oncogene TCL-1 is overexpressed in B cells, as a putative CLL model. The aim of our studies is to further characterise the mouse model using next-gen sequencing approaches. Materials and Methods: Next-geri sequencing was performed using RNA isolated from CD5+/CD19 cells from the spleens of transgenic mice. We compared the transcriptome profiles of murine leukemic cells with normal B cell subsets and a cohort of human CLL patients (Ferreira et al., 2014). Results: We show that the molecular signatures derived from CD517CD1 9+ leukemic cells from ER-TCL-1 mice are distinct from other normal B cell subsets. Strikingly, molecular signatures of these leukemias demonstrate minimal overlap with those of the those of most human population (Ferreira et al., 2014). Nonetheless, more stringent analysis revealed that the mouse model does bear a close resemblance to a subgroup of human CLL characterized by high TCLI expression. TCL1 overexpression has been associated with adverse outcome in CLL patients. Interestingly, unlike prototypical CLL disease, dysregulation of BCL-2 family protein expression was not detected in leukemic cells from Et-TCL-1 transgenic mice, which appear refractory to the inhibition of BCL2, at least in vitro. Moreover, the leukemias isolated from sick mice showed a surprisingly wide range of sensitivity to standard-of-care agents such as fludarabine. Conclusions: Taken together, our studies suggest that the leukemias which develop in ER-TCL-1 transgenic mice represent a highly aggressive, chemorefractory subtype of CLL. The goals of our ongoing studies are to further characterize this model of CLL and utilize it to test novel therapeutic approaches for treating CLL, particularly chemorefractory disease.</abstract><cop>Oxford</cop><pub>Elsevier Science Ltd</pub></addata></record>
fulltext fulltext
identifier ISSN: 0959-8049
ispartof European journal of cancer (1990), 2016-12, Vol.69, p.S110
issn 0959-8049
1879-0852
language eng
recordid cdi_proquest_journals_2037440181
source Access via ScienceDirect (Elsevier)
subjects Animal models
Bcl-2 protein
CD19 antigen
CD5 antigen
Cell culture
Chronic lymphocytic leukemia
Fludarabine
Gene expression
Gene sequencing
Hematopoietic stem cells
Human populations
Leukemia
Lymphatic leukemia
Lymphocytes B
Mice
Molecular chains
Patients
Protein expression
Proteins
Ribonucleic acid
RNA
Signatures
Stem cell transplantation
Stem cells
Subgroups
Transgenic mice
Transplantation
title The Eµ-TCL-1 mouse model of chronic lymphocytic leukemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A45%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20E%C2%B5-TCL-1%20mouse%20model%20of%20chronic%20lymphocytic%20leukemia&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Chin,%20HS&rft.date=2016-12-01&rft.volume=69&rft.spage=S110&rft.pages=S110-&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/&rft_dat=%3Cproquest%3E2037440181%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2037440181&rft_id=info:pmid/&rfr_iscdi=true